DWR 2206
Alternative Names: DWR-2206Latest Information Update: 25 Jul 2024
Price :
$50 *
At a glance
- Originator D. Western Therapeutics Institute
- Developer ActualEyes; D. Western Therapeutics Institute
- Class Cell therapies; Eye disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Eye disorders
Most Recent Events
- 31 Mar 2024 Phase-II clinical trials in Eye disorders in Japan (Parenteral) (D. Western Therapeutic Institutes pipeline, July 2024)
- 14 Jul 2022 Preclinical trials in Eye disorders in Japan (Parenteral)
- 01 Jun 2022 ActualEyes and DWTI agree to co-promote and co-develop DWR 2206 for eye disorder (DWTI pipeline-July 2022)